AVTX
Avalo Therapeutics·NASDAQ
--
--(--)
--
--(--)
AVTX fundamentals
Avalo Therapeutics (AVTX) released its earnings on Aug 7, 2025: revenue was 0 (YoY --), met estimates; EPS was -1.92 (YoY +86.35%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-1.92
+86.35%
Report date
Aug 7, 2025
EPS
Actual | -1036.8 | -518.4 | -460.8 | -460.8 | -921.6 | -518.4 | -489.6 | -460.8 | -576 | -331.2 | 81.6 | -237.6 | -204 | -141.6 | -26.4 | -10.1 | -141 | -14.07 | -2.83 | -2.3 | -1.25 | -1.92 | ||||||||
Forecast | -297.6 | -302.4 | -273.6 | -432 | -480 | -480 | -483.84 | -426.24 | -360 | -424.8 | -210.6 | -176 | -232.8 | -192 | -264 | -4.8 | -1.18 | -6.7 | -1.19 | -0.1683 | -1.332 | -1.4022 | ||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -248.39% | -71.43% | -68.42% | -6.67% | -92.00% | -8.00% | -1.19% | -8.11% | -60.00% | +22.03% | +138.75% | -35.00% | +12.37% | +26.25% | +90.00% | -110.42% | -11849.15% | -110.00% | -137.82% | -1266.61% | +6.16% | -36.93% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | 2.75M | 1.34M | 1.11M | 1.50M | 473.00K | 3.35M | 1.35M | 198.00K | 1.17M | 1.03M | 14.95M | 901.00K | 475.00K | 643.00K | 236.00K | 574.00K | 0 | 0 | 249.00K | 200.00K | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | 1.84M | 2.25M | 1.50M | 0 | 539.33K | 333.33K | 1.12M | 1.02M | 645.50K | 1.19M | 1.26M | 3.61M | 1.00M | 1.00M | 1.00M | 300.00K | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +49.46% | -40.53% | -25.93% | 0.00% | -12.30% | +906.50% | +21.01% | -80.55% | +81.72% | -12.94% | +1088.08% | -75.05% | -52.50% | -35.70% | -76.40% | +91.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
Did Avalo Therapeutics beat or miss consensus estimates last quarter?What is Avalo Therapeutics's latest dividend and current dividend yield?What is the market's earnings forecast for Avalo Therapeutics next quarter?What guidance did Avalo Therapeutics's management provide for the next earnings period?What is Avalo Therapeutics's gross profit margin?What factors drove the changes in Avalo Therapeutics's revenue and profit?What does Avalo Therapeutics do and what are its main business segments?What were the key takeaways from Avalo Therapeutics's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
